Navigation Links
Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
Date:3/23/2009

Xarelto Will Earn Decision Resources' Clinical Gold Standard Status for VTE Prophylaxis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists indicate that a therapy's effect on the prevention of venous thromboembolism (VTE) is the attribute that most influences their prescribing decisions for VTE prophylaxis in medically ill patients. Clinical data and the opinions of interviewed thought leaders indicate that Bayer/Johnson & Johnson's Xarelto has advantages in this attribute over Sanofi-Aventis's Lovenox, the sales-leading agent in the market.

The new report entitled Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy finds that an orally available therapy for VTE prophylaxis in medically ill patients would earn a 65 percent patient share in the United States and an 80 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for VTE prophylaxis in medically ill patients was GlaxoSmithKline's Arixtra, owing largely to its efficacy. Based on available data and expert opinion, Xarelto will earn gold standard status for VTE prophylaxis in medically ill patients in 2012, following its approval for the indication in 2011.

"Xarelto has competitive advantages over Arixtra in terms of delivery and safety," said Decision Resources Analyst Christine Helliwell, Ph.D. "Xarelto's main advantage is that it causes a level of bleeding similar to that of Lovenox, whereas Arixtra suffers from a perception that it causes increased rates of bleeding over Lovenox."

About the Report

Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                      Decision Resources, Inc.
    Christopher Comfort                     Elizabeth Marshall
    781-296-2597                            781-296-2563
    ccomfort@dresources.com                 emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
2. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
3. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
4. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
5. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
6. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
7. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
8. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
9. Experts from Africa and Asia to Discuss Maternal Health in Live Online Chat
10. FDA Experts to Speak at RAPS Horizons Conference
11. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)...  Mirabilis Medical, a Seattle ... surgery, announced today CE Mark authorization for marketing ... fibroids throughout the European Union.  The company simultaneously ... US Food and Drug Administration to begin a ... United States.  The Mirabilis System combines high-speed therapeutic ...
Breaking Medicine Technology: